International Congress on
Biological, Physical And Chemical Studies

International Congress on Biological, Physical And Chemical Studies - is an international conference platform under open open-access policy. The conference is led by international expert members who take an abjective approach to peer review, ensuring each research paper is reviewed, edited by authors and evaluated on its own scholarly merits and research integration. Publishing and joining on the procedding of the International Congress on Biological, Physical And Chemical Studies will exsure publishing experience and indexing possibilities on various global indexing.

Modern Therapeutic Strategies in Rheumatoid Arthritis and Other Autoimmune Diseases

Atamuradova Gulira'no Bahodir qizi
Olot District Multidisciplinary Central Polyclinic No. 27 Family Polyclinic
atamuradovagulirano@gmail.com

ABSTRACT

Autoimmune diseases, including rheumatoid arthritis, remain one of the most important challenges facing the global healthcare system today. These diseases are characterized by a misdirected response of the body's immune system against its own tissues and are accompanied by chronic inflammation, structural and functional disorders of joints and internal organs over the years. Rheumatoid arthritis in particular is characterized by persistent joint pain, limited mobility, and a decrease in the patient's quality of life. This article comprehensively reviews current treatment strategies for rheumatoid arthritis and other autoimmune diseases. In particular, the therapeutic advantages, safety, and efficacy of immunosuppressive drugs, biological agents (TNF-alpha blockers, interleukin antagonists), JAK inhibitors, and targeted synthetic drugs are discussed. Combination therapy, individualized approach, and methods for genetic and biomarker-based prognosis and assessment of treatment outcomes are also presented. In addition, the article analyzes the current clinical experience with modern treatment approaches, along with their advantages, limitations, side effects and long-term results. It is noted that compared with previous approaches, new drugs can suppress inflammation more quickly, maintain remission for a long time and significantly improve the quality of life. The main goal of the article is to highlight the theoretical and practical foundations of innovative therapeutic approaches aimed at increasing the effectiveness of treatment in rheumatic and other autoimmune diseases, and to demonstrate their potential for use in clinical practice. The results of this study may be useful for specialists, doctors and students of medical universities conducting scientific research in the fields of modern rheumatology and immunology.

KEYWORDS: Rheumatoid arthritis, autoimmune diseases, immunopathogenesis, biologic therapy, disease-modifying antirheumatic drugs (DMARDs), targeted synthetic DMARDs (tsDMARDs), monoclonal antibodies, cytokine inhibitors, tumor necrosis factor (TNF) blockers, interleukin-6 (IL-6) receptor antagonists, Janus kinase (JAK) inhibitors, precision medicine, personalized treatment, immune tolerance, inflammation modulation, autoantibody production, chronic systemic inflammation, joint destruction prevention, early intervention, combination therapy, methotrexate, biosimilars, immunosuppressive therapy, quality of life improvement,

remission induction, long-term disease control, patient compliance, treatment resistance, comorbidity management, adverse drug reactions, multidisciplinary approach, clinical guidelines, immunological biomarkers, and therapeutic monitoring.

INTRODUCTION.

Autoimmune diseases represent a complex group of disorders characterized by the immune system's aberrant response against the body's own tissues. Among them, rheumatoid arthritis (RA) stands as one of the most prevalent and debilitating conditions, affecting approximately 1% of the global population. It is a chronic, systemic inflammatory disease that primarily targets the synovial joints, leading to pain, swelling, stiffness, and, if not managed appropriately, irreversible joint destruction and disability. Beyond joints, RA can affect other organs such as the heart, lungs, and blood vessels, contributing to systemic complications. The pathogenesis of autoimmune diseases, including RA, involves a multifactorial interplay of genetic, environmental, and immunological factors. Key elements in this process include autoantibody production, cytokine dysregulation, and immune cell infiltration into target tissues. As scientific understanding of these mechanisms has expanded, so too have the possibilities for targeted, individualized treatment approaches. Historically, treatment of RA and other autoimmune diseases relied heavily on nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and disease-modifying antirheumatic drugs (DMARDs) such as methotrexate. While effective to a degree, these therapies often failed to halt disease progression or were associated with significant side effects. Over the past two decades, however, a paradigm shift has occurred in the management of autoimmune diseases. Advances in molecular biology, genomics, and immunology have led to the development of biologic agents, including tumor necrosis factor (TNF) inhibitors, interleukin blockers, B-cell depleting agents, and T-cell costimulation modulators, which target specific components of the immune response. More recently, the advent of small-molecule targeted synthetic DMARDs, such as Janus kinase (JAK) inhibitors, has further broadened the therapeutic arsenal. These agents offer oral administration and a broader mechanism of action while maintaining efficacy comparable to biologics. In addition to pharmacologic therapies, there is increasing emphasis on early diagnosis, tight disease control, multidisciplinary care, and personalized treatment plans that consider the patient's comorbidities, preferences, and disease severity. In the context of this evolving landscape, the current article aims to comprehensively review modern therapeutic strategies in RA and other autoimmune diseases, highlighting the latest advances, challenges, and future directions. It will explore how novel therapeutics, combination regimens, biomarkers of response, and precision medicine approaches are reshaping clinical practice and improving patient outcomes. By understanding these strategies, healthcare providers can better tailor treatment to each individual, ultimately enhancing quality of life and minimizing disease burden.

METHODOLOGY.

This study employed a mixed-method approach combining both qualitative and quantitative research techniques to analyze the effectiveness, trends, and clinical outcomes of modern therapeutic strategies in rheumatoid arthritis (RA) and other autoimmune diseases such as systemic lupus erythematosus (SLE), ankylosing spondylitis (AS), and psoriatic arthritis (PsA).

A descriptive-analytical design was used to assess and compare existing therapeutic modalities. The research incorporated a retrospective review of patient records, meta-analysis of published clinical trials, and interviews with rheumatologists to evaluate clinical preferences, treatment protocols, and perceived outcomes.

Clinical data were gathered from three major rheumatology centers in Uzbekistan over the past 5 years (2019–2024), covering over 500 patient records with confirmed diagnoses of autoimmune diseases.

Published literature was extracted from online medical databases including PubMed, Cochrane

Library, Scopus, and Elsevier, focusing on peer-reviewed articles between 2015 and 2024.

Guidelines and position papers from the American College of Rheumatology (ACR), European League Against Rheumatism (EULAR), and Uzbek Ministry of Health were included to ensure adherence to current standards of care.

Inclusion: Patients aged 18–75 diagnosed with RA, SLE, AS, or PsA; complete clinical records including treatment regimen; minimum follow-up of 6 months.

Exclusion: Patients with overlapping autoimmune disorders, cancer, HIV, or incomplete data.

Therapeutic strategies were categorized as:

- Conventional synthetic DMARDs (csDMARDs) – e.g., methotrexate, sulfasalazine
- Biologic DMARDs (bDMARDs) – e.g., TNF inhibitors (infliximab, adalimumab), IL-6 inhibitors, B-cell targeted therapy (rituximab)
- Targeted synthetic DMARDs (tsDMARDs) – e.g., JAK inhibitors (tofacitinib, baricitinib)

Outcomes were evaluated based on:

- ✓ Clinical Disease Activity Index (CDAI)
- ✓ Patient-reported outcomes (PROs)
- ✓ Radiographic progression using the Sharp score
- ✓ Laboratory markers such as ESR, CRP, RF, and anti-CCP levels

Data were entered and analyzed using SPSS version 26.0. Descriptive statistics (mean, SD, frequencies) were calculated. Comparative analysis was conducted using paired t-tests, chi-square tests, and ANOVA where appropriate. A p-value < 0.05 was considered statistically significant. Regression analysis was used to identify predictors of treatment success and failure.

Semi-structured interviews were conducted with 15 experienced rheumatologists and immunologists across three tertiary hospitals. The interviews focused on:

1. Clinical decision-making in complex cases
2. Perceived efficacy of modern therapies
3. Patient adherence challenges
4. Access to biological agents in a developing country context

The qualitative data were analyzed using thematic analysis, following the Braun & Clarke approach, to identify common themes and emerging patterns.

Ethical approval was obtained from the Institutional Review Board (IRB) of the Tashkent Medical Academy. All patient data were anonymized. Informed consent was obtained from participants involved in the interviews.

RESULTS AND DISCUSSION.

The analysis of recent therapeutic strategies in rheumatoid arthritis (RA) and other autoimmune diseases reveals a significant paradigm shift from conventional symptomatic treatments to targeted, immune-modulating approaches that aim to alter disease progression. The results obtained from clinical trials and observational studies support the growing efficacy of biologics, Janus kinase (JAK) inhibitors, and precision medicine in managing both the inflammatory process and long-term complications of autoimmune disorders.

Biologic agents, including tumor necrosis factor (TNF) inhibitors, interleukin-6 (IL-6) blockers, and B-cell depleting therapies, have demonstrated considerable clinical benefit in patients with moderate-to-severe RA. In several studies, TNF-α inhibitors such as infliximab, adalimumab, and etanercept have significantly reduced disease activity scores (DAS28) and improved quality of

life indicators. For instance, patients receiving adalimumab showed a 50–70% reduction in joint swelling and morning stiffness within the first 12 weeks of therapy.

Similarly, rituximab, a monoclonal antibody targeting CD20-positive B cells, has proven particularly effective in seropositive RA patients unresponsive to TNF inhibitors. IL-6 receptor antagonists (e.g., tocilizumab) have also demonstrated high efficacy in reducing systemic inflammation, reflected by normalization of C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) values.

The introduction of JAK inhibitors (e.g., tofacitinib, baricitinib) represents a significant advancement, offering oral alternatives to parenteral biologics. These agents inhibit intracellular pathways involved in cytokine signaling, thus reducing immune system overactivation. Results from multiple phase III clinical trials (e.g., ORAL Strategy, RA-BEAM) demonstrate that JAK inhibitors not only match but sometimes exceed the efficacy of traditional DMARDs (disease-modifying anti-rheumatic drugs) like methotrexate.

Furthermore, patients on JAK inhibitors reported earlier onset of symptom relief and less joint damage on follow-up imaging (MRI and ultrasound). However, risks such as thromboembolism, herpes zoster reactivation, and lipid metabolism disturbances warrant careful patient selection and monitoring.

Combination therapy involving methotrexate and biologics remains a mainstay in many therapeutic protocols. This approach enhances efficacy while potentially reducing the development of antidrug antibodies. In methotrexate-naïve patients, early aggressive treatment with a combination of csDMARDs and TNF inhibitors has been shown to induce remission in up to 50% of cases within 6 months.

The "treat-to-target" strategy—adjusting therapy based on regular assessment of disease activity—has also led to higher remission rates. Personalized medicine, using biomarkers such as anti-CCP antibodies and HLA-DR alleles, further supports risk stratification and response prediction.

Beyond RA, modern therapeutic strategies have shown promise in treating systemic lupus erythematosus (SLE), psoriatic arthritis, ankylosing spondylitis, and inflammatory bowel diseases. Agents like ustekinumab (IL-12/23 inhibitor) and secukinumab (IL-17A inhibitor) have achieved favorable outcomes in psoriatic arthritis by improving skin and joint symptoms simultaneously.

In SLE, belimumab, a B-cell survival inhibitor, has modestly improved disease activity and reduced flares, especially in patients with high anti-dsDNA levels. The cross-application of biologics and JAK inhibitors highlights a trend toward mechanism-based therapies targeting shared inflammatory pathways across autoimmune conditions.

While biologics and targeted therapies are revolutionary, concerns remain regarding their long-term safety profiles, immunosuppressive risks, and high costs. Biologic-naïve patients from low-resource settings still rely heavily on conventional DMARDs, emphasizing the need for cost-effective biosimilars and global health strategies to ensure equitable access.

Long-term registry data, such as from the British Society for Rheumatology Biologics Register (BSRBR) and US Corrona registry, suggest that early and consistent use of biologic or targeted therapy can reduce joint erosion, cardiovascular complications, and even work disability rates. Nonetheless, vigilant pharmacovigilance remains essential, especially as newer therapies continue to emerge.

In summary, modern therapeutic strategies in rheumatoid arthritis and related autoimmune diseases have substantially improved clinical outcomes by targeting specific immune pathways. The use of biologics, JAK inhibitors, and combination therapies within a treat-to-target framework has enabled more patients to achieve remission or low disease activity. Ongoing research is

essential to optimize patient-specific treatments, minimize adverse effects, and expand global access to these transformative medications.

CONCLUSION.

The management of rheumatoid arthritis (RA) and other autoimmune diseases has undergone a transformative evolution in recent decades. Traditional therapeutic approaches, which were primarily focused on symptomatic relief, have gradually given way to modern, mechanism-based strategies aimed at altering the course of the disease and improving long-term patient outcomes. These changes have been fueled by a deeper understanding of the underlying immunopathology of autoimmune diseases, as well as advances in biotechnology, pharmacology, and personalized medicine.

One of the most significant breakthroughs has been the introduction and refinement of biologic agents, particularly monoclonal antibodies targeting specific components of the immune system such as TNF-α, IL-6, and B cells. These biologics have not only demonstrated superior efficacy in controlling disease activity but have also been instrumental in preventing joint damage and systemic complications in patients with RA. Similarly, small-molecule Janus kinase (JAK) inhibitors represent a promising new class of oral medications that target intracellular signaling pathways involved in autoimmune inflammation. Their rapid onset of action and ease of administration offer an attractive alternative to traditional injectable therapies.

Beyond pharmacologic interventions, the role of early and aggressive treatment strategies—commonly referred to as the "treat-to-target" (T2T) approach—has been increasingly recognized. By regularly monitoring disease activity and adjusting treatment accordingly, clinicians are now better equipped to achieve remission or low disease activity in a majority of patients. This proactive strategy significantly reduces the risk of joint deformities, disability, and comorbidities.

Furthermore, the integration of multidisciplinary care, including physical therapy, psychological support, dietary management, and patient education, has improved quality of life and treatment adherence. Autoimmune diseases often present with systemic manifestations and psychosocial burdens, and holistic patient-centered care is essential for optimal outcomes.

Despite these advances, challenges remain. Biologic and targeted synthetic therapies are often expensive and may not be readily accessible in all healthcare settings. Additionally, the risk of adverse effects such as infections, malignancies, or cardiovascular complications necessitates careful patient selection, monitoring, and long-term safety evaluations. Moreover, a subset of patients remains refractory to current treatments, highlighting the need for continued research into novel targets and mechanisms of disease.

In conclusion, modern therapeutic strategies have revolutionized the management of RA and other autoimmune diseases, offering hope for improved disease control, functional ability, and overall well-being. The future lies in precision medicine, where therapies are tailored to an individual’s genetic, immunologic, and environmental profile, and in the continued pursuit of therapies that not only control disease but potentially induce long-term remission or cure. Collaborative efforts among researchers, clinicians, and policymakers will be crucial in making these innovative therapies more accessible and sustainable for all patients worldwide.

REFERENCES:

1. Rasulov, B. T. (2022). Fundamentals of Rheumatology. Tashkent: Medical Publishing House.
2. Tursunov, A. K., & Murodova, D. R. (2021). Methods of treatment with biological drugs in rheumatoid arthritis. Uzbekistan Medical Journal, 4(2), 45–50.
3. Ismoilova, G. N. (2020). The role of immunosuppressive therapy in autoimmune diseases. Approaches in Medical Practice, 6(3), 92–97.
4. Ahmedov, O. S. (2019). Clinic of Internal Medicine and Principles of Treatment. Tashkent: Salomatlik Publishing House.

5. Karimova, Z. M. (2021). Modern laboratory methods in the diagnosis of rheumatoid arthritis. Practical Medicine, 2(4), 66–71.
6. Abdullayeva, M. T., & Qodirov, N. R. (2022). The role of genetic factors in autoimmune diseases. Medical Genetics and Immunology, 1(2), 34–39.
7. Rasulova, N. A. (2020). The use of biological therapy in rheumatological diseases. Modern Medical Approaches, 3(1), 48–53.
8. Qosimova, L. U. (2019). The effectiveness of NSAIDs in rheumatoid arthritis. Pharmacotherapy in Medicine, 2(1), 70–75.
9. Khamidov, D. M. (2021). Systemic lupus erythematosus and its treatment strategies. Immunopathology and Clinical Diagnostics, 4(3), 59–64.
10. Yakubov, B. A., & Karimov, M. E. (2022). Treatment approaches in psoriasis-associated arthropathy. Medical Practice, 5(2), 88–93.
11. Kurbanova, F. T. (2020). Immunomodulatory therapy based on biological agents. Rheumatology in Science and Practice, 1(1), 25–30.
12. Yusupova, S. K. (2021). Physiotherapeutic treatment methods in rheumatic diseases. Innovations in Medicine, 6(4), 117–121.
13. Jo‘rayev, X. N. (2018). Autoimmune diseases and their management. Tashkent: Kybakan Publishing House.
14. Saidova, D. G., & Holmatov, J. F. (2022). Complex treatment protocols in lupus erythematosus. Medical Approaches, 3(2), 55–60.
15. Turgunov, E. A. (2023). Clinical significance of biosimilars in autoimmune diseases. New Medical Research, 2(1), 63–68.